Old Web
English
Sign In
Acemap
>
authorDetail
>
Shona Collins
Shona Collins
Celgene
Pomalidomide
Medicine
Dexamethasone
Refractory Multiple Myeloma
Multiple myeloma
5
Papers
35
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial
2018
Journal of Clinical Oncology
Meletios A. Dimopoulos
Katja Weisel
Niels W.C.J. van de Donk
Karthik Ramasamy
Barbara Gamberi
Matthew Streetly
Massimo Offidani
Frank Bridoux
Javier de la Rubia
Maria-Victoria Mateos
Antonio Ardizzoia
Elisabeth Kueenburg
Shona Collins
Antonia Di Micco
Barbara Rosettani
Yan Li
Pamela Bacon
Pieter Sonneveld
Show All
Source
Cite
Save
Citations (28)
MM-013 Phase 2, Multicenter Study of Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI): Pharmacokinetics (PK) Analysis
2017
Blood
Pieter Sonneveld
Katja Weisel
Yan Li
Elisabeth Kueenburg
Shona Collins
Antonia Di Micco
Barbara Rosettani
Pamela Bacon
Meletios A. Dimopoulos
Show All
Source
Cite
Save
Citations (0)
Phase 2 Multicenter Study of Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI): An Updated Safety Analysis
2017
Clinical Lymphoma, Myeloma & Leukemia
Katja Weisel
Meletios A. Dimopoulos
Niels W.C.J. van de Donk
Karthik Ramasamy
Barbara Gamberi
Matthew Streetly
Massimo Offidani
Frank Bridoux
Javier de la Rubia
Elisabeth Kueenburg
Shona Collins
Frederik Lersch
Barbara Rosettani
Pamela Bacon
Pieter Sonneveld
Show All
Source
Cite
Save
Citations (1)
1